

GENOMMA LAB
SECOND QUARTER
2026



Genomma Lab.®
Internacional



Genomma Lab Internacional Announces Results for the Second Quarter 2026

Mexico City, July 22, 2026 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from our CEO, Marco Sparvieri

“Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma’s market share increased or remained stable across all business units despite broad category contraction. Encouragingly, monitored retailer sell-out turned positive in the first two weeks of July, driven by the successful rollout of our innovation pipeline, particularly Suerox Mineral.

On a consolidated basis, like-for-like sales declined 3.6%, reflecting the ongoing recovery in Mexico and continued softness in the US Hispanic market, partially offset by 3.9% growth in Latin America. We expanded gross margin by 106 basis points to 64.6%, as productivity gains more than offset increased promotional investment. EBITDA margin of 21.8% came in line with our expectations, and net income grew 5.5%.

We remain confident in a gradual recovery through the second half of 2026 as we continue to execute our growth initiatives, protect market share, and maintain disciplined productivity to mitigate margin pressures. Our fundamentals remain solid, and we believe Genomma Lab is well positioned as we navigate the current consumption cycle.”

Q2 2026 Financial Summary

The following table provides a summary of the Company’s Income Statement, in millions of Mexican pesos.

	Q2 2026	% sales	Q2 2025	% sales	var %
Like-for-like Sales⁽¹⁾					-3.6%
Net Sales	4,397.0	100.0%	4,676.4	100.0%	-6.0%
Gross Profit	2,838.6	64.6%	2,969.4	63.5%	-4.4%
Operating Income	877.2	19.9%	1,030.6	22.0%	-14.9%
EBITDA⁽²⁾	958.6	21.8%	1,112.9	23.8%	-13.9%
Net Income	374.5	8.5%	355.0	7.6%	5.5%
EPS	0.37		0.35		5.5%

(1) Like-for-like (“LFL”) Sales are Net Sales expressed in constant currency and excludes the hyperinflationary subsidiary

(2) EBITDA defined as operating income before depreciation and amortization

Net Sales: Like-for-like sales declined -3.6%, reflecting the ongoing recovery in Mexico and continued disruption in the US Hispanic retail market, partially offset by a +3.9% increase in like-for-like sales in Latin America, driven by strong performance in Central America and the Andean region. Net sales decreased -6.0%, reflecting the decline in like-for-like sales and the negative foreign exchange impact from the Mexican peso’s 10.8% appreciation during the quarter.

Gross profit: Reached 64.6% margin, representing a +106 basis-point increase, as productivity gains more than offset higher promotional investment including the fully-absorbed impact of Mexico’s new tax on non-caloric sweetened beverages.

EBITDA: Reached 21.8% margin, representing a -200 basis-point decline, primarily reflecting operational deleverage. SG&A expenses remained flat, as productivity savings significantly offset higher operating expenses and inflation.

Net Income: Increased +5.5%, driven by lower financial expenses and reduced foreign exchange losses.

Regional & Business Unit Review

The following review compares regional and business unit year-over-year growth during Q2 2026 in MXN unless otherwise stated.

	Net sales			Like-for-like		Net sales			Like-for-like	
	Q2 2026	Q2 2025	Δ%	Δ%	YTD	YTD	Δ%	Δ%		
Mexico	2,074.2	2,170.5	(4.4)%	(4.4)%	3,952.0	4,225.6	(6.5)%	(6.5)%		
Latam	1,989.1	2,044.2	(2.7)%	3.9%	3,966.2	3,964.9	0.0%	4.6%		
USA	333.7	461.7	(27.7)%	(21.3)%	669.4	892.2	(25.0)%	(15.7)%		
Total Net Sales	4,397.0	4,676.4	(6.0)%	(3.6)%	8,587.7	9,082.7	(5.5)%	(3.7)%		
Beverages	853.2	744.7	14.6%	15.9%	1,613.5	1,698.2	(5.0)%	(2.3)%		
OTC	1,894.1	2,058.7	(8.0)%	(12.3)%	3,700.1	3,953.5	(6.4)%	(11.6)%		
Personal Care	1,462.8	1,695.4	(13.7)%	(11.9)%	2,918.0	3,128.6	(6.7)%	(4.3)%		
Infant Nutrition	186.9	177.6	5.2%	5.2%	356.0	302.3	17.8%	17.8%		
Total Net Sales	4,397.0	4,676.4	(6.0)%	(3.6)%	8,587.7	9,082.7	(5.5)%	(3.7)%		

Mexico: Sales performance was marked by a sequential improvement and market share growing or remaining stable amid market softness. Net sales decreased -4.4% versus deeper declines in prior periods, as strength in Beverages and Infant Nutrition helped offset softness elsewhere. Most notably, the Company grew or held market share across every single business unit on a YTD basis — a strong outcome given broad-based category contraction, in particular Isotonic Beverages (-6.6%) and OTC (-6.3%). Sell-out trends are also healing, improving sequentially to -4.0%, while the sell-in/sell-out gap narrowed to 43 basis points — a sign that channel health is improving. The innovation pipeline that launched at the end of June is already showing early traction, with monitored retailer sell-out turning positive (+2.4%) in the first two weeks of July — a promising indicator that growth initiatives are starting to resonate with consumers. The Company is leaning into this momentum with additional product launches and increased investment to defend and build share as it navigates intensified competition.

While EBITDA margin contracted -412 bps to 20.5% due to upfront investment ahead of the sales ramp-up, this was partially offset by gross margin expansion from productivity gains, reflecting disciplined cost management even while investing for future growth.

Latam (ex Arg): Like-for-like sales increased +3.9%, driven by strong performance in Central America and the Andean region, reflecting market share gains in OTC and Beverages across key markets, as well as expansion in the traditional channel. Growth initiatives continued to gain traction, supporting expectations for continued growth through the remainder of 2026.

Argentina: Local currency net sales grew +22.7% while local currency sell-out grew +37.7%, outpacing inflation by 4.5 percentage points. The sell-in/sell-out gap reflects differences in timing of channel loading compared with 2025, with heavier loading in Q1 2026 to secure shelf space ahead of the season. Sell-out growth was driven by expanded distribution and strong unit share gains across Tafirol, Suerox, Ibu, and Treg. In Mexican peso terms, net sales decreased -9.2% reflecting the impact of a 24% depreciation of the Argentine peso relative to the Mexican peso during the quarter, consistent with the hyperinflationary accounting treatment applied to the subsidiary under IAS 29.

Latam: Net sales declined -2.7%, as +3.9% like-for-like growth was offset by the appreciation of the Mexican peso relative to regional currencies. EBITDA margin, including Argentina, increased +41 basis points to 25.1%, reflecting disciplined productivity execution that more than offset foreign exchange headwinds and higher operating expenses to support growth initiatives.

U.S.: Local currency sales declined -21.3%, reflecting ongoing disruption in the U.S. Hispanic retail landscape and category-level pressure in Cough & Cold following two consecutive milder seasons. In Mexican peso terms, net sales declined -27.7%, reflecting a 10.8% appreciation of the Mexican peso relative to the U.S. dollar during the quarter. Suerox sell-out continued to grow at a double-digit rate, while the e-commerce channel further expanded. The Company is realigning its commercial footprint and distribution model to stabilize performance and support a gradual recovery. EBITDA margin decreased -585 basis points to 9.9%, primarily reflecting foreign exchange headwinds and operational deleverage.

Working Capital & Free Cash Flow

The following tables provide a summary of the Company's working capital.

	Q2 2026	Q2 2025	Δ	Q1 2026	Δ
Receivable days	113	100	13	109	4
Inventory days	112	111	1	109	3
Payable days	96	96	0	99	-3
CCC	129	115	14	119	10

Cash Conversion Cycle (CCC): Reached 129 days, a 10-day increase versus Q1 2026, driven by a 4-day increase in receivables, a 3-day increase in inventories and a 3-day decrease in payables.

The higher working capital primarily reflects a deliberate commercial investment in Mexico's receivables to support innovation launches and secure incremental shelf space during the seasonal selling period, while securing optimal supply and speed-to-market for the innovation roll-out through advanced payments and inventory building.

This strategy is contributing to improving sell-out trends in the Mexican market, amid broad-category contractions, while strengthening the Company's competitive position as new products gain traction.

Net Income: Increased +5.5%, driven by lower financial expenses and reduced foreign exchange losses, partially offset by higher inflationary loss on the Company's monetary position in its hyperinflationary subsidiary and a lower EBITDA margin.

Free Cash Flow (FCF): Decreased -53.5% to MXN 1,259.2 million on a trailing twelve-month (TTM) basis year over year, primarily reflecting lower operating income and higher working capital requirements.

Capital Allocation

Dividends. On June 29, 2026, the Company paid a cash dividend of MXN \$0.200000 per common share, totaling MXN 200 million. Genomma Lab intends to continue paying quarterly dividends.


CAPEX: Totaled MXN 120.2 million in Q2 2026. Investments in the Company's manufacturing plant and distribution center totaled MXN 102.4 million.

Key Debt Ratios

Debt Service Coverage Ratio: 5.23x

Net Debt / EBITDA: 1.38x

Cash Conversion Cycle



Figures in days

Days of Accounts Receivable (DSO)

	Q2 2026	Q2 2025	Q1 2026
Mexico	128	116	117
Latam	105	91	105
US	89	63	91
Consolidated	113	100	109

Relevant Events

[Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction](#)

[Genomma Lab Internacional Announces Sixteenth Dividend Payment](#)

Conference Call

Date: Thursday, July 23, 2026

Time: 1:00 p.m. ET | 11:00 a.m. Mexico City Time

Webcast Registration: [Genomma's Q2 2026 Earnings Call](#)

Participants:

Marco Sparvieri, CEO
Antonio Zamora, CFO
Christianne Ibanez, IRO

Contact Information:

Investor Relations

Christianne Ibanez
Daniel Suarez

Tel: +52 (55) 5081-0075
investor.relations@genommalab.com

InspIR Group

Barbara Cano
barbara@inspirgroup.com

Sell-side Analyst Coverage

As of July 22, 2026 "LABB" is covered by 9 sell-side analysts at the following brokerages: Actinver Casa de Bolsa, Banco Itaú BBA, BBVA Bancomer, BTG Pactual US Capital, GBM Grupo Bursátil Mexicano, Grupo Financiero Banorte, J.P. Morgan Securities, Jefferies Financial Group and Monex Grupo Financiero.

About

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LAB B" (Bloomberg: LABB:MM).



Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic; economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF INCOME

For the three and six months ended June 30, 2026 and 2025

Thousands of Mexican pesos	Q2					6M				
	2026	% Sales	2025	% Sales	Δ%	2026	% Sales	2025	% Sales	Δ%
Net Sales	4,397,037	100.0%	4,676,435	100.0%	(6.0)%	8,587,660	100.0%	9,082,761	100.0%	(5.5)%
Cost of goods sold	(1,558,450)	(35.4)%	(1,707,020)	(36.5)%	(8.7)%	(3,091,485)	(36.0)%	(3,346,025)	(36.8)%	(7.6)%
Gross Profit	2,838,587	64.6%	2,969,415	63.5%	(4.4)%	5,496,175	64.0%	5,736,736	63.2%	(4.2)%
Selling, general and administrative expenses	(1,884,198)	(42.9)%	(1,883,464)	(40.3)%	0.0%	(3,586,854)	(41.8)%	(3,604,133)	(39.7)%	(0.5)%
Other income (expense)	4,170	0.1%	26,985	0.6%	(84.5)%	5,610	0.1%	28,146	0.3%	(80.1)%
EBITDA	958,559	21.8%	1,112,936	23.8%	(13.9)%	1,914,931	22.3%	2,160,749	23.8%	(11.4)%
Depreciation and amortization	(81,356)	(1.9)%	(82,299)	(1.8)%	(1.1)%	(163,310)	(1.9)%	(169,489)	(1.9)%	(3.6)%
Income from operations	877,203	19.9%	1,030,637	22.0%	(14.9)%	1,751,621	20.4%	1,991,260	21.9%	(12.0)%
Interest expense	(176,650)	(4.0)%	(194,272)	(4.2)%	(9.1)%	(354,440)	(4.1)%	(414,374)	(4.6)%	(14.5)%
Interest income	29,334	0.7%	33,297	0.7%	(11.9)%	65,098	0.8%	61,543	0.7%	5.8%
Foreign exchange result	(93,695)	(2.1)%	(249,764)	(5.3)%	(62.5)%	(73,870)	(0.9)%	(266,889)	(2.9)%	(72.3)%
Inflationary result from monetary position	(101,460)	(2.3)%	(63,063)	(1.3)%	60.9%	(209,572)	(2.4)%	(113,533)	(1.2)%	84.6%
Comprehensive financing income (cost)	(342,471)	(7.8)%	(473,802)	(10.1)%	(27.7)%	(572,784)	(6.7)%	(733,253)	(8.1)%	(21.9)%
Associated company	0	0.0%	0	0.0%	n.a.	0	0.0%	0	0.0%	n.a.
Income before income taxes	534,732	12.2%	556,835	11.9%	(4.0)%	1,178,837	13.7%	1,258,007	13.9%	(6.3)%
Income tax expense	(160,239)	(3.6)%	(201,869)	(4.3)%	(20.6)%	(309,697)	(3.6)%	(404,322)	(4.5)%	(23.4)%
Net income from continuous operations	374,493	8.5%	354,966	7.6%	5.5%	869,140	10.1%	853,685	9.4%	1.8%
Results from discontinuous operations (Marzam)	0	0.0%	0	0.0%	n.a.	0	0.0%	0	0.0%	n.a.
Consolidated net income	374,493	8.5%	354,966	7.6%	5.5%	869,140	10.1%	853,685	9.4%	1.8%

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As of June 30, 2026 and 2025 and December 31, 2025

<i>Thousands of Mexican pesos</i>	As of June 30, 2026	2025	Δ%	As of December 31, 2025	Δ%
ASSETS					
Current assets					
Cash and equivalents and restricted fund	2,435,120	2,587,887	(5.9)%	3,073,169	(20.8)%
Clients - Net	5,373,055	5,233,232	2.7%	4,496,071	19.5%
Recoverable Taxes	1,655,769	1,577,438	5.0%	1,677,040	(1.3)%
Other accounts receivable*	1,145,264	838,046	36.7%	1,016,387	12.7%
Inventory - Net	1,954,882	2,124,652	(8.0)%	1,840,214	6.2%
Prepaid expenses	630,880	927,686	(32.0)%	741,837	(15.0)%
Total current assets	13,194,970	13,288,941	(0.7)%	12,844,718	2.7%
Non-current assets					
Trademarks	5,580,431	5,610,246	(0.5)%	5,529,886	0.9%
Minority Investment	200,544	0	n.a.	144,187	39.1%
Discontinued Operations	0	0	n.a.	0	n.a.
Building, properties and equipment – Net	3,950,712	3,604,365	9.6%	3,840,450	2.9%
Deferred income tax, assets and others	1,199,073	1,675,006	(28.4)%	1,279,152	(6.3)%
Assets by right of use	69,259	65,968	5.0%	52,119	32.9%
Total non-current assets	11,000,019	10,955,585	0.4%	10,845,794	1.4%
TOTAL ASSETS	24,194,989	24,244,526	(0.2)%	23,690,512	2.1%
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current Liabilities					
Short-term debt and Current portion of long-term debt	3,205,972	2,236,480	43.3%	2,799,290	14.5%
Suppliers	1,665,523	1,843,403	(9.6)%	1,580,930	5.4%
Other current liabilities	2,052,398	3,001,202	(31.6)%	2,550,817	(19.5)%
Income tax payable	263,068	185,193	42.1%	214,442	22.7%
Total current Liabilities	7,186,961	7,266,278	(1.1)%	7,145,479	0.6%
Non-current liabilities					
Long-term debt securities	3,390,017	3,384,413	0.2%	3,391,027	(0.0)%
Long-term loans with financial institutions	1,176,017	1,579,133	(25.5)%	1,378,678	(14.7)%
Deferred income tax and other long term liabilities	665,604	779,311	(14.6)%	657,287	1.3%
Payable dividends to shareholders	0	0	n.a.	0	n.a.
Total non-current Liabilities	5,231,638	5,742,857	(8.9)%	5,426,992	(3.6)%
TOTAL LIABILITIES	12,418,599	13,009,135	(4.5)%	12,572,471	(1.2)%
Stockholders' equity					
Contributed Capital	1,825,350	1,825,350	0.0%	1,825,352	(0.0)%
Retained earnings	12,872,798	12,014,828	7.1%	12,354,788	4.2%
Cumulative translation effects of foreign subsidiaries	(1,042,479)	(785,850)	32.7%	(1,214,075)	(14.1)%
Repurchased shares - Net	(1,881,617)	(1,821,275)	3.3%	(1,850,360)	1.7%
Fair value through profit OCI	2,338	2,338	0.0%	2,338	0.0%
Total Stockholders' Equity	11,776,390	11,235,391	4.8%	11,118,043	5.9%
TOTAL EQUITY AND LIABILITIES	24,194,989	24,244,526	(0.2)%	23,690,514	2.1%

Subsequent Events / Financing Update

On July 13, 2026, the Company signed a 10-year bilateral loan agreement with Bancomext for Ps. 1,500,000,000. Approximately 50% of the facility has been disbursed to date, with the remaining balance expected to be disbursed during the third quarter. The full impact of this financing will be reflected in the Company's results for the next reporting period.

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS

For the three ended June 30, 2026 and 2025

Thousands of Mexican pesos	Q2		Δ%
	2026	2025	
Cash and cash equivalents beginning of period	2,809,041	2,157,025	30.2%
Consolidated Net Income	374,493	354,966	5.5%
Charges to results with no cash flow:			
Depreciation and amortization	90,382	92,043	(1.8)%
Income tax	160,239	201,868	(20.6)%
Accrued interest and others	232,448	236,651	(1.8)%
Changes in Working Capital:			
Clients - Net	(192,778)	(102,365)	88.3%
Recoverable VAT	34,590	(58,048)	(159.6)%
Inventories	(58,937)	(58,579)	0.6%
Suppliers	(65,319)	(52,023)	25.6%
Other current assets	329,048	75,290	337.0%
Paid income tax	(138,030)	(149,014)	(7.4)%
Other current liabilities	(382,978)	(31,257)	1125.3%
Net cash generated (used) in operating activities	383,158	509,532	(24.8)%
Investing activities:			
Investment in fixed assets	(120,170)	(86,566)	38.8%
Resources from financial instruments	(19,937)	(14,675)	35.9%
Sales of equipment	51,814	2,945	1659.4%
Other asset acquisitions	(59,998)	(36,376)	64.9%
Interest collected	28,609	33,263	(14.0)%
Net cash generated (used) in investing activities	(119,682)	(101,409)	18.0%
Financing activities:			
Payments of borrowings with financial institutions	(916,846)	(2,091,270)	(56.2)%
Loans with financial and securities institutions	629,518	2,400,000	(73.8)%
Interest paid	(171,562)	(191,575)	(10.4)%
Net Stock repurchase	(4,690)	36,075	(113.0)%
Payment of liabilities for lease	(14,264)	(12,600)	13.2%
Dividends paid to shareholders	(195,006)	0	na
Net cash used in financing activities	(672,850)	140,630	(578.5)%
Net increase in cash and cash equivalents before foreign exchange adjustments coming from international operations and inflationary affects cash	(409,374)	548,753	(174.6)%
Foreign exchange and inflationary effects from international operations	35,453	(117,891)	(130.1)%
Accumulated cash flow at the end of the period	2,435,120	2,587,887	(5.9)%
Less - restricted fund	19,080	17,128	11.4%
Cash and cash equivalents at end of period balance for operation	2,416,040	2,570,759	(6.0)%

ANNEX

EXCLUSION OF IAS 29 AND IAS 21 EFFECTS

For the three and six months ended June 30, 2026 and 2025

	Reported			2026		2025		Excl. IAS 29 & 21		
	Q2 2026	Q2 2025	Δ%	Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	Q2 2026	Q2 2025	Δ%
Net Sales	4,397.0	4,676.4	(6.0)%	(12.3)	(104.0)	63.4	(186.8)	4,513.3	4,799.8	(6.0)%
EBITDA	958.6	1,112.9	(13.9)%	(0.3)	(32.4)	12.2	(56.3)	991.3	1,157.0	(14.3)%
EBITDA Margin	21.8%	23.8%						22.0%	24.1%	
Net Income	374.5	355.0	5.5%	(2.2)	(19.8)	(130.2)	(26.3)	396.5	511.4	(22.5)%
Net Margin	8.5%	7.6%						8.8%	10.7%	

	Reported			2026		2025		Excl. IAS 29 & 21		
	6M Q2 2026	6M Q2 2025	Δ%	Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	Inflation Effect (IAS 29)	Conversion Effect (IAS 21)	6M Q2 2026	6M Q2 2025	Δ%
Net Sales	8,587.7	9,082.8	(5.5)%	1.2	(87.4)	54.8	(204.3)	8,673.9	9,232.3	(6.0)%
EBITDA	1,914.9	2,160.7	(11.4)%	0.0	(27.4)	11.4	(61.2)	1,942.3	2,210.6	(12.1)%
EBITDA Margin	22.3%	23.8%						22.4%	23.9%	
Consolidated Net Income	869.1	1,881.1	(53.8)%	(219.4)	(14.8)	(235.9)	(29.6)	1,103.3	2,146.6	(48.6)%
Net Margin	10.1%	20.7%						12.7%	23.3%	



Genomma Lab Received
"HRC Equidad MX" Certificate

MSCI
ESG RATINGS



CCC B BB BBB A AA AAA

Third improvement
in last 4 yrs



EMPRESA
SOCIALMENTE
RESPONSABLE

20th consecutive
year awarded



+71,000
Medicines donated during
Q2 2026

EDGE Plus
Certificate

[Click Here](#)

